CryoLife, Inc. (NYSE:CRY) Director James Benson sold 2,000 shares of the firm’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $22.80, for a total transaction of $45,600.00. The sale was disclosed in a document filed with the SEC, which is available through this link.

Shares of CryoLife, Inc. (NYSE:CRY) traded up 0.86% on Wednesday, reaching $23.50. 172,720 shares of the company’s stock traded hands. The firm has a market capitalization of $785.98 million, a P/E ratio of 71.21 and a beta of 0.92. The company’s 50-day moving average is $21.18 and its 200-day moving average is $18.92. CryoLife, Inc. has a 52 week low of $14.03 and a 52 week high of $23.70.

CryoLife (NYSE:CRY) last released its earnings results on Monday, July 24th. The medical equipment provider reported $0.12 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.10 by $0.02. The firm had revenue of $47.80 million during the quarter, compared to analysts’ expectations of $47.02 million. CryoLife had a net margin of 6.16% and a return on equity of 7.41%. The business’s quarterly revenue was up 1.5% compared to the same quarter last year. During the same period in the prior year, the company earned $0.13 EPS. Equities research analysts anticipate that CryoLife, Inc. will post $0.43 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This story was first published by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.americanbankingnews.com/2017/10/04/james-benson-sells-2000-shares-of-cryolife-inc-cry-stock.html.

Several research analysts have weighed in on the stock. BidaskClub lowered shares of CryoLife from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. Zacks Investment Research lowered shares of CryoLife from a “buy” rating to a “sell” rating in a report on Wednesday, August 2nd. One analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. CryoLife currently has an average rating of “Hold” and a consensus price target of $22.33.

A number of large investors have recently added to or reduced their stakes in the stock. Louisiana State Employees Retirement System raised its stake in CryoLife by 0.9% during the 2nd quarter. Louisiana State Employees Retirement System now owns 11,100 shares of the medical equipment provider’s stock valued at $221,000 after purchasing an additional 100 shares during the last quarter. Municipal Employees Retirement System of Michigan raised its stake in CryoLife by 3.2% during the 1st quarter. Municipal Employees Retirement System of Michigan now owns 6,150 shares of the medical equipment provider’s stock valued at $102,000 after purchasing an additional 190 shares during the last quarter. Arizona State Retirement System raised its stake in CryoLife by 1.4% during the 1st quarter. Arizona State Retirement System now owns 14,054 shares of the medical equipment provider’s stock valued at $234,000 after purchasing an additional 200 shares during the last quarter. Creative Planning raised its stake in CryoLife by 3.0% during the 2nd quarter. Creative Planning now owns 6,806 shares of the medical equipment provider’s stock valued at $136,000 after purchasing an additional 200 shares during the last quarter. Finally, Wells Fargo & Company MN raised its stake in CryoLife by 0.9% during the 2nd quarter. Wells Fargo & Company MN now owns 31,313 shares of the medical equipment provider’s stock valued at $624,000 after purchasing an additional 271 shares during the last quarter. Hedge funds and other institutional investors own 68.44% of the company’s stock.

CryoLife Company Profile

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.

Receive News & Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related companies with MarketBeat.com's FREE daily email newsletter.